ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2019
Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?
Abstract read
In one paragraph
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.Diabetes, obesity & metabolism · 2022Trial
- Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.Alimentary pharmacology & therapeutics · 2021Trial
- Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients.Nutrients · 2021Trial
- Trial
- Adipose-Derived Mesenchymal Stem Cells and Their Exosomes Ameliorate Sperm-related Abnormalities, Hormonal Imbalance, and Disrupted Testicular Autophagy in A Diet-Induced Murine Model for Non-Alcoholic Fatty Liver Disease.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- A data-driven framework reconstructs the molecular continuum of human MASLD progression.Nature metabolism · 2026Article
- The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.Nutrients · 2026Review
- Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH.JHEP reports : innovation in hepatology · 2026Article
- Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact.Journal of health, population, and nutrition · 2025Article
- Hyperuricemia-Especially "Metabolic Hyperuricemia"-Is Independently Associated with a Higher Risk of Steatotic Liver Disease.Metabolites · 2025Article
- Resveratrol Relieves Hepatic Steatosis and Enhances the Effects of Atorvastatin in a Mouse Model of NAFLD by Regulating the Renin-Angiotensin System, Oxidative Stress, and Inflammation.Food science & nutrition · 2025Article
- Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Medicina (Kaunas, Lithuania) · 2025Review
- Bioelectrical Impedance Analysis Demonstrates Reliable Agreement with Dual-Energy X-ray Absorptiometry in Identifying Reduced Skeletal Muscle Mass in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Hypertension.Diagnostics (Basel, Switzerland) · 2024Article
- Locoregional Therapies for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.Biomedicines · 2024Review
- Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.Cancers · 2024Review
- Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.BMC primary care · 2024Article
- Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis.Journal of health economics and outcomes research · 2024Article
- The Impact and Burden of Dietary Sugars on the Liver.Hepatology communications · 2023Review
- Machine Learning Enables Single-Score Assessment of MASLD Presence and Severity.medRxiv : the preprint server for health sciences · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Lisa M Glassis a Staff Physician, and is Chief of Gastroenterology and Associate Chief of Medicine, both at VA Ann Arbor Healthcare System. is a Physician Affiliate and Director of the Cooperative Studies Program Epidemiology Centers at Durham VAMC in North Carolina. is Chief of Hepatology and Liver Transplantation at Hunter Holmes McGuire VAMC. Christine Hunt is an Adjunct Associate Professor of Medicine at Duke University Medical Center in Durham. Lisa Glass is an Assistant Professor and Grace Su is a Professor of Medicine, both at the University of Michigan Medical School in Ann Arbor. Michael Fuchs is Professor of Medicine at Virginia Commonwealth University in Richmond.
Christine M Huntis a Staff Physician, and is Chief of Gastroenterology and Associate Chief of Medicine, both at VA Ann Arbor Healthcare System. is a Physician Affiliate and Director of the Cooperative Studies Program Epidemiology Centers at Durham VAMC in North Carolina. is Chief of Hepatology and Liver Transplantation at Hunter Holmes McGuire VAMC. Christine Hunt is an Adjunct Associate Professor of Medicine at Duke University Medical Center in Durham. Lisa Glass is an Assistant Professor and Grace Su is a Professor of Medicine, both at the University of Michigan Medical School in Ann Arbor. Michael Fuchs is Professor of Medicine at Virginia Commonwealth University in Richmond.
Michael Fuchsis a Staff Physician, and is Chief of Gastroenterology and Associate Chief of Medicine, both at VA Ann Arbor Healthcare System. is a Physician Affiliate and Director of the Cooperative Studies Program Epidemiology Centers at Durham VAMC in North Carolina. is Chief of Hepatology and Liver Transplantation at Hunter Holmes McGuire VAMC. Christine Hunt is an Adjunct Associate Professor of Medicine at Duke University Medical Center in Durham. Lisa Glass is an Assistant Professor and Grace Su is a Professor of Medicine, both at the University of Michigan Medical School in Ann Arbor. Michael Fuchs is Professor of Medicine at Virginia Commonwealth University in Richmond.
Grace L Suis a Staff Physician, and is Chief of Gastroenterology and Associate Chief of Medicine, both at VA Ann Arbor Healthcare System. is a Physician Affiliate and Director of the Cooperative Studies Program Epidemiology Centers at Durham VAMC in North Carolina. is Chief of Hepatology and Liver Transplantation at Hunter Holmes McGuire VAMC. Christine Hunt is an Adjunct Associate Professor of Medicine at Duke University Medical Center in Durham. Lisa Glass is an Assistant Professor and Grace Su is a Professor of Medicine, both at the University of Michigan Medical School in Ann Arbor. Michael Fuchs is Professor of Medicine at Virginia Commonwealth University in Richmond.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvement in NAFLD may lead to improvement of metabolic syndrome, cardiovascular disease, and malignancy and vice versa.
Identifiers
PMID
30867626PMC
PMC6411365What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.